Yoltech Therapeutics, one of China’s most prolific gene editing companies has raised its biggest round of funding ahead of plans to go public in Hong Kong.

New York City-based startup Waypoint Bio has raised $20 million in series A financing to test multiple cell therapies in China.

Yoltech Therapeutics, one of China’s most prolific gene editing companies has raised its biggest round of funding ahead of plans to go public in Hong Kong.